DOCSLIB.ORG

Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas Published OnlineFirst February 15, 2011; DOI: 10.1158/0008-5472.CAN-10-2525 Cancer Therapeutics, Targets, and Chemical Biology Research Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas Tara L. Naylor1, Huaping Tang1, Boris A. Ratsch2, Andreas Enns2, Alice Loo1, Liqing Chen1, Peter Lenz3, Nigel J. Waters1, Walter Schuler4, Bernd Dorken€ 2, Yung-mae Yao1, Markus Warmuth1, Georg Lenz2, and Frank Stegmeier1 Abstract The activated B-cell–like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) correlates with poor prognosis. The ABC subtype of DLBCL is associated with constitutive activation of the NF-kB pathway, and oncogenic lesions have been identified in its regulators, including CARD11/CARMA1 (caspase recruitment domain-containing protein 11), A20/TNFAIP3, and CD79A/B. In this study, we offer evidence of therapeutic potential for the selective PKC (protein kinase C) inhibitor sotrastaurin (STN) in preclinical models of DLBCL. A significant fraction of ABC DLBCL cell lines exhibited strong sensitivity to STN, and we found that the molecular nature of NF-kB pathway lesions predicted responsiveness. CD79A/B mutations correlated with STN sensitivity, whereas CARD11 mutations rendered ABC DLBCL cell lines insensitive. Growth inhibitory effects of PKC inhibition correlated with NF-kB pathway inhibition and were mediated by induction of G1-phase cell-cycle arrest and/or cell death. We found that STN produced significant antitumor effects in a mouse xenograft model of CD79A/B-mutated DLBCL. Collectively, our findings offer a strong rationale for the clinical evaluation of STN in ABC DLBCL patients who harbor CD79 mutations also illustrating the necessity to stratify DLBCL patients according to their genetic abnormalities. Cancer Res; 71(7); 2643–53. Ó2011 AACR. Introduction (doxorubicin), vincristine (Oncovin), prednisone] chemother- apy (R-CHOP). In contrast, ABC DLBCL represents the least Diffuse large B-cell lymphoma (DLBCL) represents the most curable subtype with 3-year overall survival rates of approxi- common subtype of malignant lymphoma and is diagnosed in mately 40% (5). A hallmark of the molecular pathogenesis of more than 20,000 patients each year in the United States. It is ABC DLBCL is the constitutive activation of the NF-kB path- heterogeneous with respect to morphology, biology, and clin- way, which occurs predominantly via the CBM (Carma1- ical presentation (1). By gene expression profiling, at least 3 Bcl10-Malt1) [CARD11 (caspase recruitment domain-contain- molecular subtypes of DLBCL can be distinguished: germinal ing protein 11, also known as CARMA1)/BCL10/MALT1] center B-cell–like (GCB) DLBCL, activated B-cell–like (ABC) signaling complex that promotes cell proliferation, differen- DLBCL, and primary mediastinal B-cell lymphoma (PMBL; tiation, and suppresses apoptosis (6, 7). refs. 2–4). The molecular DLBCL subtypes not only differ Physiologically, activation of the CBM complex in B cells with respect to their gene expression patterns but also have occurs in response to B-cell receptor (BCR) stimulation. significantly different overall survival rates. GCB DLBCL Antigen binding to the BCR induces receptor oligomerization and PMBL patients respond favorably to current standard- and thereby promotes Lyn-mediated phosphorylation of of-care combined therapy with the anti-CD20 antibody ritux- ITAM (immunoreceptor tyrosine-based activation motif) imab and CHOP [cyclophosphamide, hydroxydoxorubicin domains in the B-cell coreceptors CD79A and CD79B (8). Phosphorylated ITAM domains recruit and activate the pro- tein tyrosine kinase SYK (spleen tyrosine kinase) at the plasma 1 Authors' Affiliations: Novartis Institutes for BioMedical Research, Cam- membrane that initiates downstream signaling through BTK bridge, Massachusetts; 2Department of Hematology, Oncology and Tumor Immunology, Charite, Berlin, Germany; 3Department of Physics, (Bruton's tyrosine kinase) and PLCg (phospholipase Cg) and Philipps-University Marburg, Marburg, Germany; and 4Novartis Institutes ultimately leads to the activation of PKC (protein kinase C). In for BioMedical Research, Basel, Switzerland B cells, PKCb is thought to be the predominant PKC isoform Note: Supplementary data for this article are available at Cancer Research mediating BCR-NF-kB activation, at least in part, through the Online (http://cancerres.aacrjournals.org/). phosphorylation of CARD11 (9, 10). Once activated at the Corresponding Author: Frank Stegmeier, Novartis Institutes for Bio- Medical Research, Oncology, 250 Massachusetts Avenue, 3C-282, plasma membrane, the CBM complex facilitates the activation Cambridge, MA 02139. Phone: 617-871-3736; Fax: 617-871-4000; E-mail: of the IKK (I kappa B kinase) complex, which phosphorylates [email protected] IkBa targeting it for proteosomal degradation, and thereby doi: 10.1158/0008-5472.CAN-10-2525 allows NF-kB transcription factors to enter the nucleus and Ó2011 American Association for Cancer Research. drive the expression of its target genes. www.aacrjournals.org 2643 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2011 American Association for Cancer Research. Published OnlineFirst February 15, 2011; DOI: 10.1158/0008-5472.CAN-10-2525 Naylor et al. Until recently, it was unclear whether the constitutive NF- BrdUrd (bromodeoxyuridine) incorporation (Roche). Caspase kB pathway activation in ABC DLBCL represents a primary 3/7 activity was measured using CaspaseGlo (Promega). pathogenetic event in lymphomagenesis or merely reflects the Detailed protocols are available in Supplementary Materials physiologic status of the tumor cell of origin. The identifica- and Methods. tion of oncogenic CARD11 mutations provided the first evi- dence for genetic deregulation of this pathway (11). Moreover, TaqMan mRNA expression, NF-kB nuclear recent studies have revealed somatically acquired genetic translocation, and IL-6/IL-10 secretion assay lesions in several NF-kB pathway regulators, including fre- In vivo tumor samples were harvested and snap frozen in quent loss-of-function mutations and deletions in the negative liquid nitrogen. Tissue samples were homogenized and lyzed regulator A20 (12, 13) and genetic abnormalities in CD79A and in RLT buffer with reagent DX, using the TissueLyser (Qiagen), CD79B (14). Thus, the vast majority of ABC DLBCLs seem to and mRNA expression was analyzed by TaqMan. NF-kB harbor genetic lesions that constitutively activate NF-kB translocation and interleukin (IL)-6/IL-10 secretion levels in pathway signaling. Previous studies showed that ABC DLBCL supernatants were assessed using Trans-AM (Active Motif) lines are sensitive to inhibition of CARD11, BCL10, MALT1, ELISA plates and Quantikine ELISA kits (R&D Systems), or IKKb, showing a clear dependence on NF-kB pathway respectively. Detailed protocols are available in Supplemen- signaling (6, 7, 15). These results contrast another study tary Materials and Methods. that proposed that ligand-independent "tonic" BCR signaling is a more general feature of B-cell lymphomas that renders Western blotting and gene expression analysis these cells dependent on downstream BCR signaling (16). To For Western blotting, 30 mg of protein from total cell lysate clarify the role of BCR signaling and assess the therapeutic was loaded onto 4% to 12% Bis-Tris gradient gels (Invitrogen). potential of PKC inhibitors in the treatment of DLBCL, we The following primary antibodies were used: a-CARD11, analyzed the response of DLBCL cell lines to treatment with a-cRel (Cell Signaling), a-p65 a-PARP, a-PKCb (Santa Cruz), the selective PKC inhibitor sotrastaurin (STN, also known as and GAPDH (glyceraldehyde 3-phosphate dehydrogenase; AEB071), which is currently in phase II clinical trials for Sigma). Gene expression was measured using whole-genome psoriasis and solid organ transplantation (17–20). Agilent 4  44K gene expression arrays (Agilent Technologies) following the manufacturer's protocol. Materials and Methods Detailed protocols are available in Supplementary Materials and Methods. Cell culture and cell line generation TMD8, SU-DHL4, SU-DHL2, BJAB, U2932, K422, and HBL1 Tumor xenografts cells were grown in RPMI 1640 with 10% FBS, DB cells in RPMI Mice were maintained and handled in accordance with 1640 with 20% FBS, OCI-Ly3 in Iscove's modified Dulbecco's Novartis Biomedical Research Animal Care and Use Commit- medium (IMDM) with 20% FBS, and OCI-Ly10 in IMDM with tee protocols and regulations. Treatment was initiated when 20% human serum. Cell lines were authenticated by single tumor volume reached an average size of 160 mm2 (21 days nucleotide polymorphism profiling (fingerprinting). For the post–tumor implantation). STN solution was prepared weekly RNA interference experiments, cell lines were engineered to and dosed orally on a "tid" schedule. Tumor volume was express the murine ecotropic retroviral receptor for efficient determined by twice-weekly digital calipering and calculated retroviral transductions and the bacterial tetracycline repres- using the formula: length  width2/2. Data were expressed as sor for doxycycline-inducible short hairpin RNA (shRNA) mean Æ SEM, and differences were considered statistically expression as described (7). The targeting sequence of the significant at P < 0.05 by Student t test. PKCb shRNA was CGACCAACACTGTCTCCAAAT. HBL1 cells were engineered to stably express the activat- Results ing CARD11-L244P mutation by transduction with a lentiviral vector
Load more

Recommended publications
  • Hypomorphic CARD11 Mutations Associated with Diverse Immunologic Phenotypes with Or Without Atopic Disease
    This is a repository copy of Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/135712/ Version: Accepted Version Article: Dorjbal, B, Stinson, JR, Ma, CA et al. (52 more authors) (2019) Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease. The Journal of Allergy and Clinical Immunology, 143 (4). pp. 1482-1495. ISSN 0091-6749 https://doi.org/10.1016/j.jaci.2018.08.013 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can’t change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Accepted Manuscript Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease Batsukh Dorjbal, PhD, Jeffrey R. Stinson, PhD, Chi A.
    [Show full text]
  • Lymphomagenic CARD11/BCL10/MALT1 Signaling Drives Malignant B-Cell Proliferation Via Cooperative NF-Κb and JNK Activation
    Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation Nathalie Kniesa, Begüm Alankusa, Andre Weilemannb,c, Alexandar Tzankovd, Kristina Brunnera, Tanja Ruffa, Marcus Kremere, Ulrich B. Kellerf, Georg Lenzb,c, and Jürgen Rulanda,g,h,1 aInstitut für Klinische Chemie und Pathobiochemie, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany; bTranslational Oncology, Department of Medicine A, University Hospital Münster, 48149 Münster, Germany; cCells in Motion, Cluster of Excellence EXC 1003, 48149 Münster, Germany; dInstitute of Pathology, University Hospital Basel, 4031 Basel, Switzerland; eInstitut für Pathologie, Klinikum Harlaching, 81545 Munich, Germany; fDepartment of Medicine III, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany; gGerman Cancer Consortium, 69120 Heidelberg, Germany; and hGerman Center for Infection Research, 81675 München, Germany Edited by Tak W. Mak, The Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, and approved November 12, 2015 (received for review April 16, 2015) The aggressive activated B cell-like subtype of diffuse large B-cell (PI3K) (reviewed in ref. 8). The key link to the IKK complex is lymphoma is characterized by aberrant B-cell receptor (BCR) signal- the scaffolding molecule caspase recruitment domain-containing ing and constitutive nuclear factor kappa-B (NF-κB) activation, which protein 11 (CARD11), which is inactive in resting cells due to an is required for tumor cell survival. BCR-induced NF-κBactivationre- intramolecular inhibitory interaction between its linker region quires caspase recruitment domain-containing protein 11 (CARD11), and its coiled-coil domain (9).
    [Show full text]
  • PRKCQ / PKC-Theta Antibody (Aa640-690) Rabbit Polyclonal Antibody Catalog # ALS16240
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 PRKCQ / PKC-Theta Antibody (aa640-690) Rabbit Polyclonal Antibody Catalog # ALS16240 Specification PRKCQ / PKC-Theta Antibody (aa640-690) - Product Information Application WB, IHC Primary Accession Q04759 Reactivity Human, Mouse, Rat Host Rabbit Clonality Polyclonal Calculated MW 82kDa KDa PRKCQ / PKC-Theta Antibody (aa640-690) - Additional Information Gene ID 5588 Other Names Protein kinase C theta type, 2.7.11.13, Western blot of PKC (N670) pAb in extracts nPKC-theta, PRKCQ, PRKCT from A549 cells. Target/Specificity Human PKC Theta Reconstitution & Storage Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Precautions PRKCQ / PKC-Theta Antibody (aa640-690) is for research use only and not for use in diagnostic or therapeutic procedures. Anti-PRKCQ / PKC-Theta antibody IHC staining of human brain, cerebellum. PRKCQ / PKC-Theta Antibody (aa640-690) - Protein Information PRKCQ / PKC-Theta Antibody (aa640-690) - Name PRKCQ Background Synonyms PRKCT Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent Function serine/threonine-protein kinase that mediates Calcium-independent, phospholipid- and non- redundant functions in T-cell receptor diacylglycerol (DAG)- dependent (TCR) signaling, including T-cells activation, serine/threonine-protein kinase that proliferation, differentiation and survival, by mediates non-redundant functions in T-cell mediating activation of multiple transcription receptor (TCR) signaling, including T-cells factors such as NF-kappa-B, JUN, NFATC1 and activation, proliferation, differentiation and NFATC2. In TCR-CD3/CD28-co-stimulated Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 survival, by mediating activation of multiple T-cells, is required for the activation of transcription factors such as NF-kappa-B, NF-kappa-B and JUN, which in turn are JUN, NFATC1 and NFATC2.
    [Show full text]
  • Defining the Relevant Combinatorial Space of the PKC/CARD-CC Signal Transduction Nodes
    bioRxiv preprint doi: https://doi.org/10.1101/228767; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Defining the relevant combinatorial space of the PKC/CARD-CC signal transduction nodes Jens Staal1,2,*, Yasmine Driege1,2, Mira Haegman1,2, Styliani Iliaki1,2, Domien Vanneste1,2, Inna Affonina1,2, Harald Braun1,2, Rudi Beyaert1,2 1 Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium, 2 VIB-UGent Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, Ghent, Belgium. * corresponding author: [email protected] Running title: PKC/CARD-CC signaling Abbreviations: Bcl10 = B Cell CLL/Lymphoma 10 CARD = Caspase activation and recruitment domain CC = Coiled-coil domain MALT1 = Mucosa-associated lymphoid tissue lymphoma translocation protein 1 PKC = protein kinase C Keywords: Inflammation, cancer, NF-kappaB, paracaspase Conflict of interests: The authors declare no conflict of interest. bioRxiv preprint doi: https://doi.org/10.1101/228767; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Abstract Biological signal transduction typically display a so-called bow-tie or hour glass topology: Multiple receptors lead to multiple cellular responses but the signals all pass through a narrow waist of central signaling nodes.
    [Show full text]
  • Structural Determinants of MALT1 Protease Activity
    doi:10.1016/j.jmb.2012.02.018 J. Mol. Biol. (2012) 419,4–21 Contents lists available at www.sciencedirect.com Journal of Molecular Biology journal homepage: http://ees.elsevier.com.jmb Structural Determinants of MALT1 Protease Activity Christian Wiesmann 1, Lukas Leder 1, Jutta Blank 1, Anna Bernardi 1, Samu Melkko 1, Arnaud Decock 1, Allan D'Arcy 1, Frederic Villard 1, Paulus Erbel 1, Nicola Hughes 1, Felix Freuler 1, Rainer Nikolay 1, Juliano Alves 2, Frederic Bornancin 1 and Martin Renatus 1⁎ 1Novartis Institutes for BioMedical Research, Forum 1, Novartis Campus, CH-4002 Basel, Switzerland 2Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA Received 19 December 2011; The formation of the CBM (CARD11–BCL10–MALT1) complex is pivotal received in revised form for antigen-receptor-mediated activation of the transcription factor NF-κB. 13 February 2012; Signaling is dependent on MALT1 (mucosa-associated lymphoid tissue accepted 15 February 2012 lymphoma translocation protein 1), which not only acts as a scaffolding Available online protein but also possesses proteolytic activity mediated by its caspase-like 23 February 2012 domain. It remained unclear how the CBM activates MALT1. Here, we provide biochemical and structural evidence that MALT1 activation is Edited by M. Guss dependent on its dimerization and show that mutations at the dimer interface abrogate activity in cells. The unliganded protease presents itself in Keywords: a dimeric yet inactive state and undergoes substantial conformational protease; changes upon substrate binding. These structural changes also affect the caspase; conformation of the C-terminal Ig-like domain, a domain that is required for structure; MALT1 activity.
    [Show full text]
  • Molecular Architecture and Regulation of BCL10-MALT1 Filaments
    ARTICLE DOI: 10.1038/s41467-018-06573-8 OPEN Molecular architecture and regulation of BCL10-MALT1 filaments Florian Schlauderer1, Thomas Seeholzer2, Ambroise Desfosses3, Torben Gehring2, Mike Strauss 4, Karl-Peter Hopfner 1, Irina Gutsche3, Daniel Krappmann2 & Katja Lammens1 The CARD11-BCL10-MALT1 (CBM) complex triggers the adaptive immune response in lymphocytes and lymphoma cells. CARD11/CARMA1 acts as a molecular seed inducing 1234567890():,; BCL10 filaments, but the integration of MALT1 and the assembly of a functional CBM complex has remained elusive. Using cryo-EM we solved the helical structure of the BCL10- MALT1 filament. The structural model of the filament core solved at 4.9 Å resolution iden- tified the interface between the N-terminal MALT1 DD and the BCL10 caspase recruitment domain. The C-terminal MALT1 Ig and paracaspase domains protrude from this core to orchestrate binding of mediators and substrates at the filament periphery. Mutagenesis studies support the importance of the identified BCL10-MALT1 interface for CBM complex assembly, MALT1 protease activation and NF-κB signaling in Jurkat and primary CD4 T-cells. Collectively, we present a model for the assembly and architecture of the CBM signaling complex and how it functions as a signaling hub in T-lymphocytes. 1 Gene Center, Ludwig-Maximilians University, Feodor-Lynen-Str. 25, 81377 München, Germany. 2 Research Unit Cellular Signal Integration, Institute of Molecular Toxicology and Pharmacology, Helmholtz-Zentrum München - German Research Center for Environmental Health, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany. 3 University Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale IBS, F-38044 Grenoble, France. 4 Department of Anatomy and Cell Biology, McGill University, Montreal, Canada H3A 0C7.
    [Show full text]
  • Analysis of CARD10 and CARD11 Somatic Mutations in Patients with Ovarian Endometriosis
    ONCOLOGY LETTERS 16: 491-496, 2018 Analysis of CARD10 and CARD11 somatic mutations in patients with ovarian endometriosis YANG ZOU1,2, JIANG-YAN ZHOU1,3, FENG WANG1,2, ZI-YU ZHANG1,2, FA-YING LIU1,2, YONG LUO1,2, JUN TAN1,4, XIN ZENG1, XI-DI WAN1 and OU-PING HUANG1,3 1Key Laboratory of Women's Reproductive Health of Jiangxi Province; 2Central Laboratory; 3Department of Gynecology; 4Reproductive Medicine Center, Jiangxi Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. China Received October 11, 2017; Accepted March 27, 2018 DOI: 10.3892/ol.2018.8659 Abstract. Endometriosis is a complex and heterogeneous amongst 101 cases of ovarian endometriosis for the first time, pre-malignant inflammatory disease harboring multiple these mutations may serve active roles in the development of gene mutations. Previous studies have suggested that caspase ovarian endometriosis. recruitment domain family member (CARD)10 and CARD11 mutations may exist in endometriosis. In the present study, Introduction a collection of endometriotic lesions and paired peripheral blood from 101 patients with ovarian endometriosis were Endometriosis is a heterogeneous estrogen-dependent chronic obtained, and the entire coding sequences of the CARD10 gynecological disease in women of reproductive age (1-3). The and CARD11 genes were sequenced. Evolutionary conserva- condition is characterized by endometrial tissues ectopically tion analysis and online prediction programs were applied implanting outside the uterine cavity, and is subdivided mainly to analyze the disease-causing potential of the identified into ovarian, peritoneal and deep infiltrating endometriosis mutations. A total of 4 novel somatic mutations were according to the different implant locations (4,5).
    [Show full text]
  • Rare Copy Number Variants in the Genome of Chinese Female Children and Adolescents with Turner Syndrome
    Bioscience Reports (2019) 39 BSR20181305 https://doi.org/10.1042/BSR20181305 Research Article Rare copy number variants in the genome of Chinese female children and adolescents with Turner syndrome Li Li1,*, Qingfeng Li1,*, Qiong Wang2,LiLiu3,RuLi4,HuishuLiu1, Yaojuan He1 and Gendie E. Lash2 1Department of Obstetrics and Gynecology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510160, China; 2Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510160, China; 3Department of Pediatrics Endocrinology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510160, China; 4Prenatal Diagnostic Center, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510160, China Correspondence: Li Li ([email protected]) or Gendie E. Lash ([email protected]) Turner syndrome (TS) is a congenital disease caused by complete or partial loss of one X chromosome. Low bone mineral status is a major phenotypic characteristic of TS that can not be fully explained by X chromosome loss, suggesting other autosomal-linked mutations may also exist. Therefore, the present study aimed to detect potential genetic mutations in TS through examination of copy number variation (CNV). Seventeen patients with TS and 15 healthy volunteer girls were recruited. Array-based comparative genomic hybridization (a-CGH) was performed on whole blood genomic DNA (gDMA) from the 17 TS patients and 15 healthy volunteer girls to identify potential CNVs. The abnormal CNV of one identified gene (CARD11) was verified by quantitative PCR.
    [Show full text]
  • Intrinsic Plasma Cell Differentiation Defects in B Cell Expansion with Nf-Κb and T Cell Anergy Patient B Cells
    ORIGINAL RESEARCH published: 02 August 2017 doi: 10.3389/fimmu.2017.00913 Intrinsic Plasma Cell Differentiation Defects in B Cell Expansion with NF-κB and T Cell Anergy Patient B Cells Swadhinya Arjunaraja 1, Brent D. Nosé 1, Gauthaman Sukumar 2,3, Nathaniel M. Lott 2,3, Clifton L. Dalgard 2,3 and Andrew L. Snow 1* 1 Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 2 Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 3 The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, United States B cell Expansion with NF-κB and T cell Anergy (BENTA) disease is a novel B cell lymph- oproliferative disorder caused by germline, gain-of-function mutations in the lymphocyte Edited by: scaffolding protein CARD11, which drives constitutive NF- B signaling. Despite dramatic Elissa Deenick, κ Garvan Institute of Medical polyclonal expansion of naive and immature B cells, BENTA patients also present with Research, Australia signs of primary immunodeficiency, including markedly reduced percentages of class- Reviewed by: switched/memory B cells and poor humoral responses to certain vaccines. Using purified Vanessa L. Bryant, Walter and Eliza Hall Institute for naive B cells from our BENTA patient cohort, here we show that BENTA B cells exhibit Medical Research, Australia intrinsic defects in B cell differentiation. Despite a profound in vitro survival advantage David Andrew Fulcher, relative to normal donor B cells, BENTA patient B cells were severely impaired in their Australian National University, lo hi Australia ability to differentiate into short-lived IgD CD38 plasmablasts or CD138+ long-lived Julia Ellyard, plasma cells in response to various stimuli.
    [Show full text]
  • Congenital B Cell Lymphocytosis Explained by Novel Germline CARD11 Mutations
    Article Congenital B cell lymphocytosis explained by novel germline CARD11 mutations Andrew L. Snow,1,4 Wenming Xiao,5 Jeffrey R. Stinson,4 Wei Lu,1 Benjamin Chaigne-Delalande,1 Lixin Zheng,1 Stefania Pittaluga,6 Helen F. Matthews,1 Roland Schmitz,7 Sameer Jhavar,7 Stefan Kuchen,8 Lela Kardava,2 Wei Wang,2 Ian T. Lamborn,3 Huie Jing,3 Mark Raffeld,6 Susan Moir,2 Thomas A. Fleisher,9 Louis M. Staudt,7 Helen C. Su,3 and Michael J. Lenardo1 Downloaded from http://rupress.org/jem/article-pdf/209/12/2247/1207150/jem_20120831.pdf by guest on 01 October 2021 1Lymphocyte Molecular Genetics Unit, Laboratory of Immunology; 2Immunopathogenesis Section, Laboratory of Immunoregulation; and 3Laboratory of Host Defenses; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD 20892 4Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 5Bioinformatics and Molecular Analysis Section, Division of Computational Bioscience, Center for Information Technology, NIH, Bethesda, MD 20892 6Laboratory of Pathology and 7Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 8Genomics and Immunity Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD 20892 9Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD 20892 Nuclear factor-B (NF-B) controls genes involved in normal lymphocyte functions, but constitutive NF-B activation is often associated with B cell malignancy. Using high- throughput whole transcriptome sequencing, we investigated a unique family with hereditary polyclonal B cell lymphocytosis. We found a novel germline heterozygous missense mutation (E127G) in affected patients in the gene encoding CARD11, a scaffolding protein required for antigen receptor (AgR)–induced NF-B activation in both B and T lymphocytes.
    [Show full text]
  • Structures of Autoinhibited and Polymerized Forms of CARD9 Reveal Mechanisms of CARD9 and CARD11 Activation
    ARTICLE https://doi.org/10.1038/s41467-019-10953-z OPEN Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation Michael J. Holliday 1, Axel Witt1, Alejandro Rodríguez Gama2, Benjamin T. Walters 3, Christopher P. Arthur4, Randal Halfmann2,5, Alexis Rohou 4, Erin C. Dueber1 & Wayne J. Fairbrother 1 1234567890():,; CARD9 and CARD11 drive immune cell activation by nucleating Bcl10 polymerization, but are held in an autoinhibited state prior to stimulation. Here, we elucidate the structural basis for this autoinhibition by determining the structure of a region of CARD9 that includes an extensive interface between its caspase recruitment domain (CARD) and coiled-coil domain. We demonstrate, for both CARD9 and CARD11, that disruption of this interface leads to hyperactivation in cells and to the formation of Bcl10-templating filaments in vitro, illumi- nating the mechanism of action of numerous oncogenic mutations of CARD11. These structural insights enable us to characterize two similar, yet distinct, mechanisms by which autoinhibition is relieved in the course of canonical CARD9 or CARD11 activation. We also dissect the molecular determinants of helical template assembly by solving the structure of the CARD9 filament. Taken together, these findings delineate the structural mechanisms of inhibition and activation within this protein family. 1 Early Discovery Biochemistry Department, Genentech, South San Francisco, CA 94080, USA. 2 Stowers Institute for Medical Research, Kansas City, MO 64110, USA. 3 Biochemical and Cellular Pharmacology Department, Genentech, South San Francisco, CA 94080, USA. 4 Structural Biology Department, Genentech, South San Francisco, CA 94080, USA. 5 Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
    [Show full text]
  • Casein Kinase 1Α: Biological Mechanisms and Theranostic Potential Shaojie Jiang1†, Miaofeng Zhang2†, Jihong Sun1 and Xiaoming Yang1,3*
    Jiang et al. Cell Communication and Signaling (2018) 16:23 https://doi.org/10.1186/s12964-018-0236-z REVIEW Open Access Casein kinase 1α: biological mechanisms and theranostic potential Shaojie Jiang1†, Miaofeng Zhang2†, Jihong Sun1 and Xiaoming Yang1,3* Abstract Casein kinase 1α (CK1α) is a multifunctional protein belonging to the CK1 protein family that is conserved in eukaryotes from yeast to humans. It regulates signaling pathways related to membrane trafficking, cell cycle progression, chromosome segregation, apoptosis, autophagy, cell metabolism, and differentiation in development, circadian rhythm, and the immune response as well as neurodegeneration and cancer. Given its involvement in diverse cellular, physiological, and pathological processes, CK1α is a promising therapeutic target. In this review, we summarize what is known of the biological functions of CK1α, and provide an overview of existing challenges and potential opportunities for advancing theranostics. Keywords: Casein kinase 1α,Wnt/β-catenin signaling, NF-κB signaling, Hedgehog signaling, Autophagy, Neurodegenerative disease, Cell cycle, Host defense response Background deletion of chromosome 5q [MDS del(5q)] that exerts Casein kinase 1α (CK1α)(encodedbyCSNK1A1 in its effects by inducing CK1α ubiquitination and degrad- humans) is a member of the CK1 family of proteins that ation [12, 13]. These findings suggest that CSNK1A1 is has broad serine/threonine protein kinase activity [1–4] a conditionally essential malignancy gene and a poten- (Fig. 1a) and is one of the main components of the Wnt/ tial target for anti-cancer drugs. β-catenin signaling pathway. CK1α phosphorylates β-catenin at Ser45 as part of the β-catenin destruction com- α plex for subsequent β-transducin repeat-containing E3 ubi- Overview of CK1 quitin protein ligase (β-TrCP)-mediated ubiquitination and CSNK1A1 is located on chromosome 5q32 and is proteasomal degradation [5, 6].
    [Show full text]